Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | CTSK | P43235 | 2/20 | 0.49 |
| ▸ | CTSL | P07711 | 2/20 | 0.49 |
| ▸ | CTSB | P07858 | 1/20 | 0.49 |
| ▸ | ELANE | P08246 | 1/20 | 0.47 |
| ▸ | PREP | P48147 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | HRH2 | P25021 | 3/20 | 0.44 |
| ▸ | HRH1 | P35367 | 3/20 | 0.44 |
| ▸ | CTSS | P25774 | 1/20 | 0.41 |
| ▸ | CCR1 | P32246 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5143005 | 0.91 | KMT2A (0.47) | KMT2AMEN1CTSKCTSLCTSB | |
| SCHEMBL5142639 | 0.91 | KMT2A (0.47) | KMT2AMEN1CTSKCTSLCTSB | |
| SCHEMBL5142586 | 0.89 | KMT2A (0.46) | KMT2AMEN1CTSKCTSLCTSB | |
| SCHEMBL4682461 | 0.88 | HRH2 (0.47) | KMT2AMEN1CTSKCTSLCTSB | |
| SCHEMBL19982033 | 0.88 | CTSK (0.54) | KMT2AMEN1CTSKCTSLCTSB | |
| SCHEMBL4684724 | 0.86 | KMT2A (0.48) | KMT2AMEN1CTSKCTSLCTSB | |
| SCHEMBL19981944 | 0.85 | KMT2A (0.55) | KMT2AMEN1CTSKCTSLCTSB | |
| SCHEMBL19981901 | 0.85 | KMT2A (0.55) | KMT2AMEN1CTSKCTSLCTSB | |
| SCHEMBL2775499 | 0.85 | KMT2A (0.55) | KMT2AMEN1CTSKCTSLCTSB | |
| SCHEMBL9546846 | 0.84 | KMT2A (0.54) | KMT2AMEN1CTSKCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1409479-B1 | 1-GLYCINYL-4-(1-METHYLPIPERIDIN-4-YL)PIPERAZINES AND -PIPERIDINES AS FACTOR XA ANTAGONISTS | LILLY CO ELI (US) | 2008-01-23 | — | — | EP | disclosed |
| US-7265121-B2 | Chemical compounds | ELI LILLY AND COMPANY (US) | 2007-09-04 | — | — | US | disclosed |
| US-20050026928-A1 | Chemical compounds | ELI LILLY AND COMPANY | 2005-02-03 | — | — | US | disclosed |
| EP-1409479-A2 | 1-GLYCINYL-4-(1-METHYLPIPERIDIN-4-YL)PIPERAZINES AND -PIPERIDINES AS FACTOR XA ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2004-04-21 | — | — | EP | disclosed |
| WO-2003010160-A2 | 1-GLYCINYL-4 (METHYLPIPERIDIN-4-YL) PIPERAZINES AND -PIPERRIDINES AS FACTOR XA ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2003-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026928-A1 | Chemical compounds | F2, F12, F11 | KMT2A 2093/4885MEN1 429/4885CTSK 2639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.